Expanded Access

WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer

06/14/2019

WideTrial , one of TrialStat’s strategic partners has partnered with Oncotelic to bring the Expanded Access Platform to Cancer. June 03, 2019 (ACCESSWIRE via COMTEX) — SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary…

Read More

FDA to Launch Expanded Access Pilot ‘Project Facilitate’

06/02/2019

The goal of Project Facilitate is to make it easier for oncologists or healthcare providers without the regulatory experience or resources to navigate the single patient IND process. “Access to clinical trials and access to novel therapeutics for patients is still a problem. We know that not all oncologists or healthcare providers have the regulatory…

Read More

Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access –Looking Forward

05/26/2019

In March of 2019 the FDA released this statement regarding the value of Expanded Access Programs and the FDA’s encouragement of Sponsors to consider providing them as options for Patient Populations. A few interesting statements worth highlighting in the statement: “Since 2010, drug sponsors and manufacturers have given the opportunity of such access to more…

Read More

You're Going to be Amazed By TrialStat

With TrialStat your studies will run smoothly, on-time and within budget.

Your Study Coordinators will enjoy the intuitive user interface and the speed in which they can enter their data. Schedule your personalized demo today to see first hand how TrialStat will transform your studies!

Close